351324-70-4

Basic information

• Product Name: tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate
• Synonyms: tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate;tert-butyl 7-aMino-1,2,3,4-tetrahydroquinoline-1-carboxylate;7-Amino-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;tert-Butyl 7-amino-3,4-dihydroquinoline-1(2H)
• CAS NO: 351324-70-4
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.3208
• Mol File: 351324-70-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 393.4°C at 760 mmHg
• Flash Point: 191.7°C
• Appearance: /
• Density: 1.145g/cm³
• Vapor Pressure: 2.13E-06mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.92±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate(351324-70-4)
• EPA Substance Registry System: tert-butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate(351324-70-4)

Safety Data

• Hazardous Substances Data: 351324-70-4(Hazardous Substances Data)

Usage

Uses

tert-Butyl 7-amino-3,4-dihydroquinoline-1(2H)-carboxylate is a useful reactant for the synthesis of organic compounds.

InChI:InChI=1/C14H20N2O2/c1-14(2,3)18-13(17)16-8-4-5-10-6-7-11(15)9-12(10)16/h6-7,9H,4-5,8,15H2,1-3H3

Upstream product

• 1236060-43-7 7-nitro-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 30450-62-5 7-nitro-1,2,3,4-tetrahydro-quinoline 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Non-peptidic NPY Y2 receptor inhibitors

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.